Article Versions Notes

Palmerini E, Pazzaglia L, Cevolani L, Pratelli L, Pierini M, Quattrini I, Carretta E, Manara MC, Pasello M, Frega G, et al. Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. Cancers. 2022; 14(12):2863. https://doi.org/10.3390/cancers14122863

Palmerini, Emanuela, Laura Pazzaglia, Luca Cevolani, Loredana Pratelli, Michela Pierini, Irene Quattrini, Elisa Carretta, Maria Cristina Manara, Michela Pasello, Giorgio Frega, and et al. 2022. "Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study" Cancers 14, no. 12: 2863. https://doi.org/10.3390/cancers14122863

Palmerini, E., Pazzaglia, L., Cevolani, L., Pratelli, L., Pierini, M., Quattrini, I., Carretta, E., Manara, M. C., Pasello, M., Frega, G., Paioli, A., Longhi, A., Cesari, M., Hakim, R., Ibrahim, T., Campanacci, L., Staals, E. L., Donati, D. M., Benassi, M. S., ... Ferrari, S. (2022). Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. Cancers, 14(12), 2863. https://doi.org/10.3390/cancers14122863